eXIthera is an early stage biotech company focused on developing small molecule pharmaceuticals to inhibit Factor Xla, an important enzyme in the blood coagulation pathway.
Inappropriately activated clotting can lead to serious consequences including venous thromboembolism, deep vein thrombosis, stroke and heart attack. The novel drugs being developed by eXIthera, unlike all presently approved anticoagulants/antithrombotics, are expected to prevent thrombosis without causing bleeding.
eXIthera Pharmaceuticals is an early stage biotech company focused on discovering and developing Factor XIa inhibitors for the prevention of stroke and thrombosis.
Blood coagulation is an important part of the host defense mechanism required for repair and maintenance of the circulatory system. This complex and multifactorial process has been described to contain two parallel but distinct pathways; hemostasis and thrombosis.